GSK plc announced data from across its respiratory portfolio will be presented in 43 abstracts, including four late-breaking submissions, at the 2025 American Thoracic Society (ATS) International Congress in… read more.
The FDA has approved Dupixent (dupilumab) for the treatment of adults and adolescents aged 12 years and older with chronic spontaneous urticaria (CSU) who remain symptomatic despite histamine-1… read more.
Hip replacement surgery, or total hip arthroplasty (THA), can lessen pain and improve function in individuals with hip osteoarthritis, but some patients continue to experience long-term physical deficits—including… read more.
Artificial intelligence (AI) tools significantly improve the readability of online patient education materials (PEMs), making them more accessible, a new study shows. Led by researchers at NYU Langone… read more.
NICE (UK) is unable to make a recommendation about the use in the NHS of pegylated liposomal irinotecan plus oxaliplatin, 5-fluorouracil and leucovorin for untreated metastatic pancreatic cancer… read more.
A recent randomized controlled trial reveals the potential of a program designed to connect patients who have breast cancer to needed exercise and rehabilitation services starting at diagnosis… read more.
Cross Country Healthcare (NASDAQ: CCRN), a leader in workforce solutions and tech-enabled staffing, recruitment and advisory services, today released its fourth annual survey, “Beyond the Bedside: The State of… read more.
Bristol Myers Squibb announced that the FDA approved Opdivo (nivolumab) plus Yervoy (ipilimumab) as a first-line treatment for adult patients with unresectable or metastatic hepatocellular carcinoma (HCC), the… read more.
Dr. Ho Sang Jung and his research team from the Advanced Bio and Healthcare Materials Research Division at the Korea Institute of Materials Science (KIMS), in collaboration with Seoul… read more.
Even for patients covered by Medicare, annual out-of-pocket costs for lifesaving cancer treatments taken in pill form have often exceeded $10,000—until recently. Thanks to changes in Medicare Part… read more.
UCB announced long-term data from the BE HEARD trials for Bimzelx (bimekizumab) in moderate to severe hidradenitis suppurativa (HS). These two-year data, building on the established efficacy profile… read more.
Researchers from the University of Missouri School of Medicine have shed new light on how the uterus develops, leading to a better understanding of female reproductive health while providing clues… read more.
If you're a healthcare professional you can sign up to our mailing list to receive high quality medical, pharmaceutical and healthcare E-Mails and E-Journals. Get the latest news and information across a broad range of specialities delivered straight to your inbox.
You can unsubscribe at any time using the 'Unsubscribe' link at the bottom of all our E-Mails, E-Journals and publications.
